Frontiers in Medicine · Nov 2, 2026
Can Continuous Glucose Monitors Improve Body Weight or Adiposity in Adults With or at Risk for Type 2 Diabetes? A Systematic Review and Meta-Analysis of Randomized Controlled Trials
By Crystal Romero, Arch Mainous, Ariel Pomputius et al.
Background: Obesity is a global disease with significant morbidity and mortality. Continuous glucose monitors (CGMs) have been investigated as wearables to reinforce healthy lifestyles in adults with or at risk of type 2 diabetes (T2DM), but their impact on body weight and composition remains uncertain. This study aimed to determine the effectiveness of CGM as a tool for improving body weight or adiposity during behavior modification. Methods: We searched five databases for randomized controlled trials from 1999 through February 2026. Populations with T2DM, prediabetes, or overweight/obesity were included. Studies on type 1 or gestational diabetes, newly diagnosed T2DM, or remote/AI-based coaching were excluded. Dual-independent screening was employed, with a third reviewer resolving disagreements. Risk of bias was evaluated using the Cochrane Risk of Bias Tool (RoB 1). Studies with comparable body weight or adiposity outcomes were pooled using a fixed-effect model to calculate mean differences with 95% confidence intervals. Heterogeneity was assessed using I² and certainty of evidence GRADE. Results: Seven of 1,995848 screened articles met eligibility criteria. Risk of bias was low to unclear across most domains except participant and personnel blinding which was high across studies. Four studies demonstrated significant reductions in weight, BMI, and/or fat mass, although the effects were modest over 8-week to 12-month follow-up periods. Four studies revealed significant behaviors modification. Five studies measuring weight change were pooled in a meta-analysis where CGM was associated with a significantly greater reduction in body weight versus control (mean difference=−1.21; 95% CI −1.88 to −0.54; p=0.0004), with low–moderate, non-significant heterogeneity (I²=22%; p=0.27). Conclusion: CGM was associated with a reduction in body weight vs control (–1.21 kg) and with favorable changes in behavior modification in select studies, aligning with a gradual approach to sustained weight loss. Further trials should focus on populations with a narrower metabolic risk and consistently include direct measures of adiposity to determine whether larger treatment effects are detectable beyond weight loss.